NEW
YORK, Oct. 31, 2023 /PRNewswire/ -- The Gross
Law Firm issues the following notice to shareholders
of Tandem Diabetes Care, Inc..
Shareholders who purchased shares of TNDM during the class
period listed are encouraged to contact the firm regarding possible
lead plaintiff appointment. Appointment as lead plaintiff is not
required to partake in any recovery.
CONTACT US HERE:
https://securitiesclasslaw.com/securities/tandem-loss-submission-form/?id=53541&from=4
CLASS PERIOD: August 3,
2022 to November 2, 2022
ALLEGATIONS: According to the complaint, defendants
provided investors with material information concerning Tandem's
projected revenue and sales for the year ending 2022. On
August 2, 2022, Tandem estimated
annual sales "to be in the range of $835
million to $845 million, which
represents an annual growth of 19 percent to 20 percent compared to
2021." Defendants provided these statements to investors while, at
the same time, disseminating materially false and misleading
statements and/or concealing material adverse facts. The
truth emerged on November 2, 2022
when Tandem, in an investment call and Form 8-K filing, revised its
2022 forecast downward to $800 to
$805 million. Reasons stated
for the scale back included increased competition in the diabetes
care sector, complications due to the COVID pandemic, and
macroeconomic factors such as inflation. Investors and analysts
reacted immediately to Tandem's revised guidance. The price of
Tandem's common stock declined dramatically. On November 2, 2022, Tandem closed at $51.34; however, on November 3, 2022 Tandem closed at $35.72 – a one-day decline of 30.4%.
DEADLINE: November 7, 2023
Shareholders should not delay in registering for this class action.
Register your information here:
https://securitiesclasslaw.com/securities/tandem-loss-submission-form/?id=53541&from=4
NEXT STEPS FOR SHAREHOLDERS: Once you register as a
shareholder who purchased shares of TNDM during the timeframe
listed above, you will be enrolled in a portfolio monitoring
software to provide you with status updates throughout the
lifecycle of the case. The deadline to seek to be a lead plaintiff
is November 7, 2023. There is no cost
or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally
recognized class action law firm, and our mission is to protect the
rights of all investors who have suffered as a result of deceit,
fraud, and illegal business practices. The Gross Law
Firm is committed to ensuring that companies adhere to responsible
business practices and engage in good corporate citizenship. The
firm seeks recovery on behalf of investors who incurred losses when
false and/or misleading statements or the omission of material
information by a company lead to artificial inflation of the
company's stock. Attorney advertising. Prior results do not
guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
View original
content:https://www.prnewswire.com/news-releases/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-tandem-diabetes-care-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-november-7-2023--nasdaq-tndm-301972142.html
SOURCE The Gross Law Firm